Liposarcoma
‘Most important study’ in soft tissue sarcomas in decades shows benefit of immunotherapy
CHICAGO — The addition of immunotherapy to radiation therapy and surgery significantly extended DFS for certain patients with soft tissue sarcoma, according to results of a randomized phase 2 trial.
VIDEO: Studies in progress generate ‘much to look forward to in sarcoma science’
“There are many exciting studies in progress to look forward to” at future Connective Tissue Oncology Society meetings, according to Candace Haddox, MD.
VIDEO: Studies focusing on understanding tumor biology could advance sarcoma field
In this video, Candace Haddox, MD, discussed a few presentations from the Connective Tissue Oncology Society Annual Meeting that focused on how better understanding of sarcoma biology could lead to clinical advancement.
VIDEO: ‘Compelling’ data on MDM2 inhibitor for liposarcoma
Sandra D’Angelo, MD, discussed initial phase 1A/1B data from a clinical trial on the efficacy and safety of BI-907828, a MDM2 inhibitor, in patients with liposarcoma presented at the Connective Tissue Oncology Society Annual Meeting.
Phase 3 trial of milademetan in dedifferentiated liposarcoma fails to meet primary endpoint
Milademetan failed to significantly extend PFS among patients with dedifferentiated liposarcoma, according to topline data released by the agent’s manufacturer.
MDM2 inhibitor shows efficacy in dedifferentiated liposarcomas, other cancers
Intermittent milademetan appeared effective and mitigated dose-limiting hematologic adverse events among patients with advanced solid tumors and lymphomas, according to study results published in Journal of Clinical Oncology.